Published in final edited form as:

Org Lett. 2011 May 20; 13(10): 2786–2788. doi:10.1021/ol200977u.

Asymmetric Enzymatic Glycosylation of Mitoxantrone

Maoquan Zhou and Jon S. Thorson

Pharmaceutical Sciences Division, School of Pharmacy, Wisconsin Center for Natural Products Research, University of Wisconsin-Madison, 777 Highland Ave. Madison, WI 53705

Jon S. Thorson: jsthorson@pharmacy.wisc.edu

Abstract

Using a uniquely promiscuous engineered glycosyltransferase (GT) derived from the macrolide-inactivating GT OleD, a single-step asymmetric glucosylation of one ‘arm’ of the drug mitoxantrone was efficiently achieved in high stereo- and regiospecificity. The synthesis, structural elucidation, and anticancer activity of the corresponding mitoxantrone 4'-β-D-glucoside are described.

The synthetic anthracenedione mitoxantrone (MXT) was developed as a drug in the 1970s and has been used in the treatment of metastatic breast cancer, acute myeloid leukemia, non-Hodgkin's lymphoma and prostate cancer.¹ MXT is a topoisomerase II inhibitor and its more recently recognized immunomodulatory properties have expanded the utility of this drug to include treatment for patients with secondary-progressive, progressive-relapsing, or worsening relapsing-remitting multiple sclerosis (MS).² In addition, MXT has demonstrated notable *in vivo* efficacy in animal models for rheumatoid arthritis³ and was also recently found to be an efficient anti-tuberculosis agent, functioning via inhibition of a specific mycobacterial kinase (PknB) which controls pathogen growth.⁴ However, the side effects associated with MXT treatment, most notably irreversible cardiomyopathy, continues to spur efforts in generating analogues which achieve a broader therapeutic window (i.e., increased potency and reduced cardiotoxicity).⁵

Toward this goal, many anthracenedione analogs have been generated.^{6,7} These studies have illuminated the impact of the C1 and C4 phenolic hydroxyl groups upon both anticancer potency and cardiotoxicity.⁸ In general, substitution on the anthraquinone core diminished the activity. In addition, all nitrogen atoms were found to be critical as was the linker length between the nitrogen atoms and the basicity of terminal amines. Removal of one ‘arm’ was also found to be detrimental and, while a number of symmetrical di-substituted MXT conjugates have been generated (including amino acid,⁹ galactose,¹⁰ netropsin¹¹ and protein¹²), the symmetry of MXT has proven to be a significant barrier to regioselective modification.^{9–12,13} Herein we report that an engineered glycosyltransferase variant (OleD ASP)¹⁴ surprisingly leads to the regio- and stereoselective modification of one ‘arm’ of

Correspondence to: Jon S. Thorson, jsthorson@pharmacy.wisc.edu.

Supporting Information Available: Experimental procedures, figures and characterization of compounds and comprehensive assay data, and NMR spectra. This material is available free of charge via the Internet at <http://pubs.acs.org>.

MXT, providing a single unique MXT-glucoside that retains notable anticancer activity. This study reveals one of the first reported single-step asymmetric MXT modification strategies and highlights the synthesis of one of the only reported MXT mono-glycosides to date. In addition, this work exposes an unexpected specificity for OleD ASP, a GT previously believed to primarily target aromatic nucleophiles.^{14a,15}

Streptomyces antibioticus OleD catalyzes the transfer of glucose (from UDP-Glc) to various macrolide antibiotics as a means of self-resistance in macrolide-producing organisms (Figure 1a).¹⁶ Directed evolution of OleD and subsequent screening for variants capable of glycosylating the model fluorescent coumarin acceptor 4-methyl umbelliferone led to the discovery of a triple mutant (OleD ASP) with a notably expanded donor and acceptor flexibility.¹⁴ Preliminary LC-MS assessment of the OleD ASP acceptor flexibility revealed OleD ASP to glycosylate a diverse range of 'drug-like' scaffolds including anthraquinones, indolocarbозoles, polyenes, cardenolides, steroids, macrolides, beta-lactams, and enediynes (Figure 1b).¹⁷ Among the agents identified as putative substrates in this study, MXT led to a mono-glycosylated species based upon LC-MS. Based upon the established bias of OleD ASP toward aromatic nucleophiles, the putative OleD ASP-catalyzed MXT glycosylation was predicted to occur at C1 or C4. This postulation was also consistent with the known glucuronidation of C1 hydroxyl group as part of MXT metabolism in vivo.¹⁸

To set the stage for a scale-up reaction to provide sufficient material for both full product characterization and biological evaluation, the pilot scale reaction conditions were first optimized. OleD variants (wt and ASP) were first overproduced and purified as previously described.¹⁴ Figure 2 highlights the outcome of a representative reaction containing 0.25 mM MTX as the acceptor, 1.25 mM UDP-glucose (UDP-Glc) as the donor, 0.5 $\mu\text{g } \mu\text{l}^{-1}$ purified OleD ASP as catalyst in 50 mM Tris HCl (pH 8.0), 5 mM MgCl_2 incubated at 25 °C for 16 hr.¹⁷ For the preparative scale reaction, MTX (5.6 mg, 12.6 μmol) was dissolved in 0.62 ml DMSO and transferred to 50 ml assay buffer solution (50 mM Tris HCl, 5 mM MgCl_2 , pH 8.0). The reaction was initiated via addition of UDP-Glc (38 mg, 0.062 mmol) and 32 mg of OleD ASP. After 27 hours of agitation at room temperature, the reaction was frozen and lyophilized to dryness. The residue was dissolved in methanol and subjected to HPLC purification to give MXT monoglucoside product (2.5 mg, 4.1 μmol) in 33% yield.

HiResMALDI-FTMS analysis of purified glucoside yielded an $[\text{M} + \text{H}]^+$ ion at m/z 607.26132 and $[\text{M} + \text{Na}]^+$ ion at m/z 629.24306, confirming a monoglucoside of mitoxantrone with a formula of $\text{C}_{28}\text{H}_{38}\text{N}_4\text{O}_{11}$ (calcd for $\text{C}_{28}\text{H}_{39}\text{N}_4\text{O}_{11}$, 607.26098, $\text{C}_{28}\text{H}_{38}\text{N}_4\text{O}_{11}\text{Na}$, 629.24293). ^1H and ^{13}C NMR along with gCOSY, TOCSY, gHSQCTOXY, gHMQC, and gHMBC data support the C4' β -D-glucosidic structure presented in Figure 3 (see Supporting Information for complete ^1H and ^{13}C NMR assignments). The key evidence for C4' glycosylation derives from the HMBC correlation between the anomeric proton and the C4' carbon while the large coupling constant (7.5 Hz) of the anomeric proton (δ_{H} 4.23, doublet) serves as key signature for the β -anomer. That OleD ASP catalysis led to asymmetric regioselective modification of a single MXT 'arm' was surprising given the bias for this evolved catalyst for aromatic nucleophiles.^{14a,15}

The cytotoxicity of the MXT 4'- β -D-glucoside (**4**, Figure 3) was evaluated in three human cancer cell lines including liver (Hep3B), breast (MCF7 and MDA MB231) and leukemia (K562) with MXT (the parent compound) as the comparator (Table 1). Interestingly, the MXT β -D-glucoside retained notable potency, with IC_{50} values below a threshold of 60 nM (~4–8- fold the activity of the parent drug) in three out of four cell lines tested. This stands in marked contrast to prior glycosides reported, such as the mitoxantrone 4',4'- β -di-D-galactoside, which was inactive.¹⁰ Given that glycosylation of pharmaceutically important compounds can often markedly alter key pharmacological properties including drug

pharmacokinetics and distribution,¹⁹ it is reasonable to assume the MXT 4'- β -D-glucoside may offer the potential for a distinct toxicity profile from that of the parent drug.

In summary, this study is noteworthy both from the perspective of catalyst development as well as therapeutic lead development. From the perspective of catalyst development, this work uncovered a unique activity of an engineered glycosyltransferase (OleD ASP) that enabled the first regio- and stereoselective asymmetric glucosylation of a single 'arm' of the anticancer drug mitoxantrone (MXT). This efficient and specific single-step enzymatic reaction is also advantageous as it requires no protecting group or sugar activation manipulations. From a therapeutic lead perspective, this work highlighted the synthesis of the first mono-glucoside of MXT and the first glycoside to show comparable anticancer activity to the parent. Given that glucosylation of pharmaceutically important compounds can often markedly alter corresponding pharmacokinetics and distribution, it is reasonable to assume that the MXT 4'- β -D-glucoside may offer a potentially beneficial toxicity profile which might be further optimized via glycodiversification methods.^{20,21}

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the School of Pharmacy Analytical Instrumentation Center for analytical support and the Keck UWCCC Small Molecule Screening Facility for cancer cell line cytotoxicity screening. J.S.T holds the Laura and Edward Kremers Chair in Natural Products. This work was supported by NIH AI52218.

References

1. (a) Van der Graaf W, Vries ED. *Anti-Cancer Drug*. 1990; 1:109–125. (b) Weiss RB. *Oncology* (Basel). 1989; 3:135–147. (b) Legha SS. *Drugs Today*. 1984; 20:629–638.
2. (a) Marriott JJ, Miyasaki JanisM, Gronseth Gary, O'Connor PaulW. *Neurology*. 2010; 74:1463–1470. [PubMed: 20439849] (b) Riahi S, Ganjali MR, Dinarvand R, Karamdoust S, Bagherzadeh K, Norouzi P. *Chem. Biol. Drug. Des.* 2008; 71:474–482. [PubMed: 18384527] (c) Fox E. *Clin. Ther.* 2006; 28:461–474. [PubMed: 16750460] (d) Scott LJ, Figgitt DP. *CNS Drugs*. 2004; 18:379–396. [PubMed: 15089110] (e) Mazerski J, Martelli S, Borowski E. *Acta Biochim. Pol.* 1998; 45:1–11. [PubMed: 9701490]
3. Verdrengh M, Isaksson O, Tarkowski A. *Rheumatology*. 2005; 44:183–186. [PubMed: 15494349]
4. Wehenkel A, Fernandez P, Bellinzoni M, Catherinot V, Barilone N, Labesse G, Jackson M, Alzari PM. *FEBS Lett.* 2006; 580:3018–3022. [PubMed: 16674948]
5. (a) Fulbright JM, Huh W, Anderson P, Chandra J. *Curr. Oncol. Rep.* 2010; 12:411–419. [PubMed: 20820959] (b) Cavalletti E, Crippa L, Mainardi P, Oggioni N, Cavagnoli R, Bellini O, Sala F. *Invest. New Drugs*. 2007; 25:187–195. [PubMed: 17285358] (c) Evison BJ, Mansour O, Menta E, Phillips DR, Cutts SM. *Nucleic Acids Res.* 2007; 35:3581–3589. [PubMed: 17483512]
6. (a) Cheng CC, Zee-Cheng RKY. Ellis GP, West GB. *Progress in Medicinal Chemistry*. 1983; Vol. New York Elsevier: 20. 83 and ref cited therein. (b) Zee-Cheng RKY, Cheng CCJ. *Med. Chem.* 1978; 21:291–294. (c) White RJ, Durr FE. *Invest. New Drug*. 1985; 3:85–93.
7. (a) Liu Y, Peacey E, Dickson J, Donahue CP, Zheng S, Varani G, Wolfe MS. *J. Med. Chem.* 2009; 52:6523–6526. [PubMed: 19839622] (b) Johnson MG, et al. *Bioorg. Med. Chem.* 1997; 5:1469–1479. [PubMed: 9313853] (c) Pors K, Shnyder SD, Teesdale-Spittle PH, Hartley JA, Zloh M, Searcey M, Patterson LH. *J. Med. Chem.* 2006; 49:7013–7023. [PubMed: 17125254] (d) Krapcho AP, Landi JJ Jr, Shaw KJ, Phinney DG, Hacker MP, McCormack JJ. *J. Med. Chem.* 1986; 29:1370–1373. [PubMed: 3735305]
8. Removal of the hydroxyl groups lower cardiotoxicity as in ametantrone, see Corbett TH, Griswold DP Jr, Roberts BJ, Schabel M Jr. *Cancer Chemother. Pharmacol.* 1981; 6:161–168. [PubMed: 6946879]

9. (a) Hsin L-W, Wang H-P, Kao P-H, Lee O, Chen W-R, Chen H-W, Guh J-H, Chan Y-L, Hi C-P, Yang M-S, Li T-K, Lee C-H. *Bioorg. Med. Chem.* 2008; 16:1006–1014. [PubMed: 17962028] (b) Zagotto G, Sissi C, Gatto B, Palumbo Manlio. *ARKIVOC.* 2004; V:204–218.
10. (a) Naleway, JJ.; Howard, RA. U.S. Patent 11/316,114. US 2006/0105915 A1. 2006 May 18. (b) Naleway, JJ.; Howard, RA. W.O. Patent. 01/02020 A2. 2001 Jan 11.
11. Boitte N, Pommery N, Colson P, Houssier C, Waring MJ, Hénichart JP, Bailly C. *Anticancer Drug Des.* 1997; 12:481–501. [PubMed: 9311557]
12. Wirth M, Gabor F, Pittner F, Schalkhammer T. *Scientia Pharmaceutica.* 1996; 64:737–744.
13. Liu W-S, Huang Y, Zhang Z-R. *Arch. Pharm. Res.* 2003; 26:892–897. [PubMed: 14661852]
14. (a) Williams GJ, Zhang C, Thorson JS. *Nat. Chem. Biol.* 2007; 3:657–662. [PubMed: 17828251] (b) Williams GJ, Thorson JS. *Nat. Protoc.* 2008; 3:357–362. [PubMed: 18323806] (c) Williams GJ, Goff RD, Zhang C, Thorson JS. *Chem Biol.* 2008; 15:393–401. [PubMed: 18420146]
15. Yang M, Proctor MR, Bolam DN, Errey JC, Field RA, Gilbert HJ, Davis BG. *J. Am. Chem. Soc.* 2005; 127:9336–9337. [PubMed: 15984838]
16. (a) Quirós LM, Carbajo RJ, Salas JA. *FEBS Lett.* 2000; 476:186–189. [PubMed: 10913610] (b) Quirós LM, Carbajo RJ, Braña AF, Salas JA. *J. Biol. Chem.* 2000; 275:11713–11720. [PubMed: 10766792] (c) Bolam DN, Roberts S, Proctor MR, Turkenburg JP, Dodson EJ, Martinez-Fleites C, Yang M, Davis BG, Davies GJ, Gilbert H. *Proc. Natl. Acad. Sci. USA.* 2007; 104:5336–5341. [PubMed: 17376874]
17. Gantt RW, Goff RD, Williams GJ, Thorson JS. *Angew. Chem. Int. Ed.* 2008; 47:8889–8892.
18. (a) Mian J, Mewes K, Ehninger G, Proksch B, Greger B, Waidelich D, Zeller K-P. *Cancer Res.* 1991; 57:3427–3433. (b) Mewes K, Blanz J, Ehninger G, Gebhardt R, Zeller K-P. *Cancer Res.* 1993; 53:5135–5142. [PubMed: 8221649]
19. (a) Weymouth-Wilson AC. *Nat. Prod. Rep.* 1997; 14:99–110. [PubMed: 9149408] (b) Langenhan JM, Griffith BR, Thorson JS. *J. Nat. Prod.* 2005; 68:1696–1711. [PubMed: 16309329] (c) Krěň V, Rěžanka T. *FEMS Microbiol. Rev.* 2008; 32:858–889. [PubMed: 18647177] (d) Williams GJ, Gantt RW, Thorson JS. *Curr. Opin. Chem. Biol.* 2008; 12:556–564. [PubMed: 18678278] (e) La Ferla B, Airolidi C, Zona C, Orsato A, Cardona F, Merlo S, Sironi E, D'Orazio G, Nicotra F. *Nat. Prod. Rep.* 2011; 28:630–648. [PubMed: 21120227]
20. (a) Fu X, Albermann C, Jiang J, Liao J, Zhang C, Thorson JS. *Nat. Biotechnol.* 2003; 21:1467–1469. [PubMed: 14608364] (b) Hoffmeister D, Yang J, Liu L, Thorson JS. *Proc. Natl. Acad. Sci. USA.* 2003; 100:13184–13189. [PubMed: 14612558] (c) Fu X, Albermann C, Zhang C, Thorson JS. *Org Lett.* 2005; 7:1513–1515. [PubMed: 15816740] (d) Zhang C, Albermann C, Fu X, Thorson JS. *J. Am. Chem. Soc.* 2006; 128:16420–16421. [PubMed: 17177349] (e) Zhang C, Moretti R, Jiang J, Thorson JS. *ChemBioChem.* 2008; 9:2506–2514. [PubMed: 18798210] (f) Williams GJ, Yang J, Zhang C, Thorson JS. *ACS Chem. Biol.* 2011; 6:95–100. [PubMed: 20886903]
21. UDP-Xyl, UDP-GlcNH₂, or UDP-GlcNHAc with OleD ASP led to conversions of < 5% while OleD mutant AIP (reference 14c) provided 16% conversion with UDP-Xyl.

Figure 1.

a) Macrolide-inactivating reaction catalyzed by wtOleD (wild type OleD); b) General *in vitro* reaction of OleDs with variant aglycons, X = O, S, NH, or NR.

Figure 2. OleD ASP catalyzed glycosylation reaction of mitoxantrone and RP-HPLC analysis of pilot scale reaction. Assay and HPLC conditions are available in Supporting Information.

Figure 3. Key ^1H and ^{13}C NMR data and gHMBC correlations of MXT 4'- β -D-glucoside

Table 1

Cancer cell line cytotoxicity (nM).

compound	Hep3B	MCF7	MDA MB231	K562
MXT (3)	15 ± 2	2 ± 0.1	11 ± 0.6	490 ± 23
MXT-D-Glc (4)	54 ± 1	16 ± 0.3	44 ± 0.2	<i>a</i>

^a > highest dose tested (1 μM)